Multilayer Capsules of Bovine Serum Albumin and Tannic Acid for Controlled Release by Enzymatic Degradation

Maria V. Lomova, Anna I. Brichkina, Maxim V. Kiryukhin, Elena N. Vasina, Anton M. Pavlov, Dmitry A. Gorin, Gleb B. Sukhorukov, Maria N. Antipina

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

With the purpose to replace expensive and significantly cytotoxic positively charged polypeptides in biodegradable capsules formed via Layer-by-Layer (LbL) assembly, multilayers of bovine serum albumin (BSA) and tannic acid (TA) are obtained and employed for encapsulation and release of model drugs with different solubility in water: hydrophilic-tetramethylrhodamine-isothiocyanate-labeled BSA (TRITC-BSA) and hydrophobic 3,4,9,10-tetra-(hectoxy-carbonyl)-perylene (THCP). Hydrogen bonding is proposed to be predominant within thus formed BSA/TA films. The TRITC-BSA-loaded capsules comprising 6 bilayers of the protein and polyphenol are benchmarked against the shells composed of dextran sulfate (DS) and poly-l-arginine (PARG) on degradability by two proteolytic enzymes with different cleavage site specificity (i.e., α-chymotrypsin and trypsin) and toxicity for murine RAW264.7 macrophage cells. Capsules of both types possess low cytotoxicity taken at concentrations equal or below 50 capsules per cell, and evident susceptibility to α-chymotrypsin resulted in release of TRITC-BSA. While the BSA/TA-based capsules clearly display resistance to treatment with trypsin, the assemblies of DS/PARG extensively degrade. Successful encapsulation of THCP in the TRITC-BSA/TA/BSA multilayer is confirmed, and the release of the model drug is observed in response to treatment with α-chymotrypsin. The thickness, surface morphology, and enzyme-catalyzed degradation process of the BSA/TA-based films are investigated on a planar multilayer comprising 40 bilayers of the protein and polyphenol deposited on a silicon wafer. The developed BSA/TA-based capsules with a protease-specific degradation mechanism are proposed to find applications in personal care, pharmacology, and the development of drug delivery systems including those intravenous injectable and having site-specific release capability. (Figure Presented).

Original languageEnglish
Pages (from-to)11732-11740
Number of pages9
JournalACS Applied Materials and Interfaces
Volume7
Issue number22
DOIs
Publication statusPublished - 10 Jun 2015
Externally publishedYes

Fingerprint

Tannins
Bovine Serum Albumin
Capsules
Multilayers
Degradation
Acids
Perylene
Arginine
Dextran
Dextran Sulfate
Encapsulation
Chymotrypsin
Polyphenols
Peptide Hydrolases
Proteins
Macrophages
Polypeptides
Cytotoxicity
Silicon wafers
Silicon

Keywords

  • controlled release
  • encapsulation
  • enzymatic degradation
  • layer-by-layer
  • protein
  • tannic acid

ASJC Scopus subject areas

  • Materials Science(all)
  • Medicine(all)

Cite this

Lomova, M. V., Brichkina, A. I., Kiryukhin, M. V., Vasina, E. N., Pavlov, A. M., Gorin, D. A., ... Antipina, M. N. (2015). Multilayer Capsules of Bovine Serum Albumin and Tannic Acid for Controlled Release by Enzymatic Degradation. ACS Applied Materials and Interfaces, 7(22), 11732-11740. https://doi.org/10.1021/acsami.5b03263

Multilayer Capsules of Bovine Serum Albumin and Tannic Acid for Controlled Release by Enzymatic Degradation. / Lomova, Maria V.; Brichkina, Anna I.; Kiryukhin, Maxim V.; Vasina, Elena N.; Pavlov, Anton M.; Gorin, Dmitry A.; Sukhorukov, Gleb B.; Antipina, Maria N.

In: ACS Applied Materials and Interfaces, Vol. 7, No. 22, 10.06.2015, p. 11732-11740.

Research output: Contribution to journalArticle

Lomova, MV, Brichkina, AI, Kiryukhin, MV, Vasina, EN, Pavlov, AM, Gorin, DA, Sukhorukov, GB & Antipina, MN 2015, 'Multilayer Capsules of Bovine Serum Albumin and Tannic Acid for Controlled Release by Enzymatic Degradation', ACS Applied Materials and Interfaces, vol. 7, no. 22, pp. 11732-11740. https://doi.org/10.1021/acsami.5b03263
Lomova, Maria V. ; Brichkina, Anna I. ; Kiryukhin, Maxim V. ; Vasina, Elena N. ; Pavlov, Anton M. ; Gorin, Dmitry A. ; Sukhorukov, Gleb B. ; Antipina, Maria N. / Multilayer Capsules of Bovine Serum Albumin and Tannic Acid for Controlled Release by Enzymatic Degradation. In: ACS Applied Materials and Interfaces. 2015 ; Vol. 7, No. 22. pp. 11732-11740.
@article{60e6ff66e1a14b78bc6a1f44b2d79518,
title = "Multilayer Capsules of Bovine Serum Albumin and Tannic Acid for Controlled Release by Enzymatic Degradation",
abstract = "With the purpose to replace expensive and significantly cytotoxic positively charged polypeptides in biodegradable capsules formed via Layer-by-Layer (LbL) assembly, multilayers of bovine serum albumin (BSA) and tannic acid (TA) are obtained and employed for encapsulation and release of model drugs with different solubility in water: hydrophilic-tetramethylrhodamine-isothiocyanate-labeled BSA (TRITC-BSA) and hydrophobic 3,4,9,10-tetra-(hectoxy-carbonyl)-perylene (THCP). Hydrogen bonding is proposed to be predominant within thus formed BSA/TA films. The TRITC-BSA-loaded capsules comprising 6 bilayers of the protein and polyphenol are benchmarked against the shells composed of dextran sulfate (DS) and poly-l-arginine (PARG) on degradability by two proteolytic enzymes with different cleavage site specificity (i.e., α-chymotrypsin and trypsin) and toxicity for murine RAW264.7 macrophage cells. Capsules of both types possess low cytotoxicity taken at concentrations equal or below 50 capsules per cell, and evident susceptibility to α-chymotrypsin resulted in release of TRITC-BSA. While the BSA/TA-based capsules clearly display resistance to treatment with trypsin, the assemblies of DS/PARG extensively degrade. Successful encapsulation of THCP in the TRITC-BSA/TA/BSA multilayer is confirmed, and the release of the model drug is observed in response to treatment with α-chymotrypsin. The thickness, surface morphology, and enzyme-catalyzed degradation process of the BSA/TA-based films are investigated on a planar multilayer comprising 40 bilayers of the protein and polyphenol deposited on a silicon wafer. The developed BSA/TA-based capsules with a protease-specific degradation mechanism are proposed to find applications in personal care, pharmacology, and the development of drug delivery systems including those intravenous injectable and having site-specific release capability. (Figure Presented).",
keywords = "controlled release, encapsulation, enzymatic degradation, layer-by-layer, protein, tannic acid",
author = "Lomova, {Maria V.} and Brichkina, {Anna I.} and Kiryukhin, {Maxim V.} and Vasina, {Elena N.} and Pavlov, {Anton M.} and Gorin, {Dmitry A.} and Sukhorukov, {Gleb B.} and Antipina, {Maria N.}",
year = "2015",
month = "6",
day = "10",
doi = "10.1021/acsami.5b03263",
language = "English",
volume = "7",
pages = "11732--11740",
journal = "ACS applied materials & interfaces",
issn = "1944-8244",
publisher = "American Chemical Society",
number = "22",

}

TY - JOUR

T1 - Multilayer Capsules of Bovine Serum Albumin and Tannic Acid for Controlled Release by Enzymatic Degradation

AU - Lomova, Maria V.

AU - Brichkina, Anna I.

AU - Kiryukhin, Maxim V.

AU - Vasina, Elena N.

AU - Pavlov, Anton M.

AU - Gorin, Dmitry A.

AU - Sukhorukov, Gleb B.

AU - Antipina, Maria N.

PY - 2015/6/10

Y1 - 2015/6/10

N2 - With the purpose to replace expensive and significantly cytotoxic positively charged polypeptides in biodegradable capsules formed via Layer-by-Layer (LbL) assembly, multilayers of bovine serum albumin (BSA) and tannic acid (TA) are obtained and employed for encapsulation and release of model drugs with different solubility in water: hydrophilic-tetramethylrhodamine-isothiocyanate-labeled BSA (TRITC-BSA) and hydrophobic 3,4,9,10-tetra-(hectoxy-carbonyl)-perylene (THCP). Hydrogen bonding is proposed to be predominant within thus formed BSA/TA films. The TRITC-BSA-loaded capsules comprising 6 bilayers of the protein and polyphenol are benchmarked against the shells composed of dextran sulfate (DS) and poly-l-arginine (PARG) on degradability by two proteolytic enzymes with different cleavage site specificity (i.e., α-chymotrypsin and trypsin) and toxicity for murine RAW264.7 macrophage cells. Capsules of both types possess low cytotoxicity taken at concentrations equal or below 50 capsules per cell, and evident susceptibility to α-chymotrypsin resulted in release of TRITC-BSA. While the BSA/TA-based capsules clearly display resistance to treatment with trypsin, the assemblies of DS/PARG extensively degrade. Successful encapsulation of THCP in the TRITC-BSA/TA/BSA multilayer is confirmed, and the release of the model drug is observed in response to treatment with α-chymotrypsin. The thickness, surface morphology, and enzyme-catalyzed degradation process of the BSA/TA-based films are investigated on a planar multilayer comprising 40 bilayers of the protein and polyphenol deposited on a silicon wafer. The developed BSA/TA-based capsules with a protease-specific degradation mechanism are proposed to find applications in personal care, pharmacology, and the development of drug delivery systems including those intravenous injectable and having site-specific release capability. (Figure Presented).

AB - With the purpose to replace expensive and significantly cytotoxic positively charged polypeptides in biodegradable capsules formed via Layer-by-Layer (LbL) assembly, multilayers of bovine serum albumin (BSA) and tannic acid (TA) are obtained and employed for encapsulation and release of model drugs with different solubility in water: hydrophilic-tetramethylrhodamine-isothiocyanate-labeled BSA (TRITC-BSA) and hydrophobic 3,4,9,10-tetra-(hectoxy-carbonyl)-perylene (THCP). Hydrogen bonding is proposed to be predominant within thus formed BSA/TA films. The TRITC-BSA-loaded capsules comprising 6 bilayers of the protein and polyphenol are benchmarked against the shells composed of dextran sulfate (DS) and poly-l-arginine (PARG) on degradability by two proteolytic enzymes with different cleavage site specificity (i.e., α-chymotrypsin and trypsin) and toxicity for murine RAW264.7 macrophage cells. Capsules of both types possess low cytotoxicity taken at concentrations equal or below 50 capsules per cell, and evident susceptibility to α-chymotrypsin resulted in release of TRITC-BSA. While the BSA/TA-based capsules clearly display resistance to treatment with trypsin, the assemblies of DS/PARG extensively degrade. Successful encapsulation of THCP in the TRITC-BSA/TA/BSA multilayer is confirmed, and the release of the model drug is observed in response to treatment with α-chymotrypsin. The thickness, surface morphology, and enzyme-catalyzed degradation process of the BSA/TA-based films are investigated on a planar multilayer comprising 40 bilayers of the protein and polyphenol deposited on a silicon wafer. The developed BSA/TA-based capsules with a protease-specific degradation mechanism are proposed to find applications in personal care, pharmacology, and the development of drug delivery systems including those intravenous injectable and having site-specific release capability. (Figure Presented).

KW - controlled release

KW - encapsulation

KW - enzymatic degradation

KW - layer-by-layer

KW - protein

KW - tannic acid

UR - http://www.scopus.com/inward/record.url?scp=84935889247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935889247&partnerID=8YFLogxK

U2 - 10.1021/acsami.5b03263

DO - 10.1021/acsami.5b03263

M3 - Article

VL - 7

SP - 11732

EP - 11740

JO - ACS applied materials & interfaces

JF - ACS applied materials & interfaces

SN - 1944-8244

IS - 22

ER -